Ludwig-Maximilians-Universität München
print

Language Selection

Breadcrumb Navigation


Content

Too much of a good thing

Overstimulation can reduce the efficacy of immune therapy

Munich, 06/29/2011

Small synthetic molecules can be used to stimulate the receptors that activate the innate immune system, and this strategy has already been successfully applied for local therapy of certain types of skin tumors. However, so far it has not been possible to stimulate the immune system in such a way as to allow this approach to be used for systemic therapy of other types of cancer. A research team led by Professor Dr. Carole Bourquin of the Division of Clinical Pharmacology at the Medical Center of the University of Munich has now shown that the timing of drug administration plays a crucial role in determining the clinical response. Stimulating the targeted receptor too often  results in what is known as receptor tolerance. The receptor becomes unresponsive to the drug, and further doses fail to have any effect.  It is therefore crucial that the drug be given at carefully chosen intervals. “Based on our data, we were able to design a more potent strategy, which was effective in reducing tumor size in mice,” says Bourquin. The results of the study could lead to more efficient therapeutic regimes for the systemic treatment of tumors in humans - and are probably relevant for other classes of therapy that are based on the stimulation of the innate immune system.

The innate immune system is capable of recognizing foreign substances and invading cells, and mobilizes various immune defense mechanisms to disable and destroy invasive pathogens. In addition, it can recognize and eliminate abnormal or otherwise damaged “self” cells, and thus provides a means of defense against tumors. These natural defense mechanisms can be exploited in a directed fashion by using small synthetic molecules of appropriate design to stimulate the receptors that form the frontline of the innate immune system.

One of these receptors is the so-called Toll-like receptor 7 (TLR7). Synthetic ligands are available that stimulate the receptor, allowing tumor tissue to be effectively recognized as foreign, and be attacked by the immune system. One particular synthetic TLR7 ligand called imiquimod is already in use for topical therapy of skin tumors. However, attempts to use the agent for the systemic therapy of other types of tumor have met with less success. “In these cases the TLR7 ligands are injected into the bloodstream several times a week. We therefore asked whether this regime of repeated stimulation might not lead to systemic immune tolerance, which would account for the limited efficacy of the treatment,” explains Bourquin.

And indeed, the researchers found that repeated administration of the synthetic ligand over a relatively short period led to the induction of receptor tolerance. The response of TLR7 was blunted, and the receptor remained refractory to restimulation for up to five days. “Frequent immune stimulation could therefore be responsible for the weak impact of the therapy,” says Bourquin. Not content with a simple error analysis, the team developed an alternative treatment schedule based on their findings. This regimen did not provoke receptor tolerance and resulted in a marked reduction in the size of tumors in mice, in spite of the fact that the total dose used was lower than that employed in the more conventional approach.

“Our study shows that the timing of systemic therapy with TLR7 ligands plays a decisive role in determining clinical efficacy,” says Bourquin, “and our results are of immediate relevance for similar studies in humans and for immune therapy in general.” Indeed, given that receptor tolerance is a widespread phenomenon, the new insights are very probably applicable to the design of other immune-based therapies also. (göd/PH)

Publication:
Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance.
C. Bourquin, C. Hotz, D. Noerenberg, A. Voelkl, S. Heidegger, L.C.M. Roetzer, B. Storch, N. Sandholzer, C. Wurzenberger, D. Anz, S. Endres.
Cancer Research. Published online, June 22, 2011.
doi:10.1158/0008-5472.CAN-10-3903

Contact:
Prof. Dr. Carole Bourquin
Division of Clinical Pharmacology, Medical Center of the University of Munich
Phone: +49 89 / 5160 - 7331
Fax: +49 89 / 5160 - 7330
Email: carole.bourquin@med.lmu.de

Responsible for content: Communications & Media Relations